Angiodynamics initiates recover-av clinical trial assessing alphavac f18⁸⁵ system in treatment of pulmonary embolism and long-term functional outcomes

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of the prospective, multicenter, multi-national, single arm trial evaluating the efficacy, safety and long term functional outcomes of percutaneous mechanical aspiration thrombectomy for treatment of acut.
ANGO Ratings Summary
ANGO Quant Ranking